← All news
Markets

New data could widen use of AstraZeneca, Amgen immune disease drug

1 source ·1 article ·Aug 27, 15:58 UTC Astrazeneca Amgen

Tezspire succeeded in a study in eosinophilic esophagitis, which could become the drug’s third approved indication and unlock what’s viewed as a blockbuster opportunity.

Covered by 1 outlet

All coverage · 1 article